Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2024 | 774 | 1.330 |
Why?
|
| Neoplasms | 11 | 2024 | 2794 | 1.200 |
Why?
|
| Parents | 3 | 2022 | 1024 | 0.960 |
Why?
|
| Allopurinol | 4 | 2023 | 70 | 0.800 |
Why?
|
| Mercaptopurine | 4 | 2022 | 71 | 0.790 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2019 | 109 | 0.700 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 427 | 0.570 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 260 | 0.540 |
Why?
|
| Cephalosporins | 1 | 2017 | 138 | 0.520 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 668 | 0.510 |
Why?
|
| Physicians | 1 | 2021 | 581 | 0.470 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2023 | 185 | 0.470 |
Why?
|
| Renal Insufficiency | 1 | 2017 | 238 | 0.460 |
Why?
|
| Cranial Irradiation | 1 | 2012 | 69 | 0.380 |
Why?
|
| Fertility Preservation | 2 | 2023 | 53 | 0.370 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 2371 | 0.370 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2022 | 13 | 0.340 |
Why?
|
| Hematologic Neoplasms | 2 | 2024 | 277 | 0.320 |
Why?
|
| Antioxidants | 1 | 2012 | 355 | 0.320 |
Why?
|
| Hospitalization | 6 | 2024 | 1784 | 0.320 |
Why?
|
| Cerebellar Neoplasms | 1 | 2012 | 443 | 0.290 |
Why?
|
| Adolescent | 20 | 2024 | 19414 | 0.290 |
Why?
|
| Health Status Disparities | 2 | 2021 | 228 | 0.280 |
Why?
|
| Medulloblastoma | 1 | 2012 | 548 | 0.270 |
Why?
|
| Child | 22 | 2024 | 24610 | 0.260 |
Why?
|
| Medical Oncology | 3 | 2023 | 220 | 0.260 |
Why?
|
| Mental Disorders | 1 | 2012 | 827 | 0.230 |
Why?
|
| Humans | 32 | 2024 | 125110 | 0.220 |
Why?
|
| Male | 19 | 2024 | 61443 | 0.210 |
Why?
|
| Thioguanine | 2 | 2022 | 21 | 0.210 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2022 | 19 | 0.200 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 3675 | 0.200 |
Why?
|
| Shock | 1 | 2023 | 91 | 0.200 |
Why?
|
| Boston | 2 | 2021 | 109 | 0.200 |
Why?
|
| Cancer Care Facilities | 1 | 2021 | 31 | 0.190 |
Why?
|
| Down Syndrome | 1 | 2024 | 198 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 3175 | 0.180 |
Why?
|
| Fever | 1 | 2024 | 297 | 0.180 |
Why?
|
| Female | 18 | 2024 | 66704 | 0.180 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 86 | 0.180 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 164 | 0.180 |
Why?
|
| Young Adult | 8 | 2024 | 9056 | 0.180 |
Why?
|
| Mycoses | 1 | 2021 | 118 | 0.170 |
Why?
|
| Maintenance Chemotherapy | 2 | 2023 | 18 | 0.160 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2022 | 522 | 0.150 |
Why?
|
| Cross Infection | 1 | 2022 | 313 | 0.150 |
Why?
|
| Trichosporonosis | 1 | 2018 | 8 | 0.150 |
Why?
|
| Invasive Fungal Infections | 1 | 2018 | 13 | 0.150 |
Why?
|
| Communication | 1 | 2022 | 507 | 0.150 |
Why?
|
| Clinical Trials as Topic | 1 | 2023 | 1095 | 0.150 |
Why?
|
| Hypoglycemia | 2 | 2018 | 191 | 0.150 |
Why?
|
| Opportunistic Infections | 1 | 2018 | 78 | 0.140 |
Why?
|
| Child, Preschool | 8 | 2024 | 14152 | 0.140 |
Why?
|
| Bacteremia | 1 | 2022 | 400 | 0.140 |
Why?
|
| Hospitals, Pediatric | 1 | 2022 | 768 | 0.140 |
Why?
|
| Sepsis | 1 | 2022 | 483 | 0.140 |
Why?
|
| Cardiomyopathies | 1 | 2022 | 500 | 0.140 |
Why?
|
| Fever of Unknown Origin | 1 | 2017 | 45 | 0.130 |
Why?
|
| Quality of Life | 2 | 2023 | 1906 | 0.130 |
Why?
|
| Neutropenia | 2 | 2018 | 196 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 293 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 1714 | 0.130 |
Why?
|
| Methotrexate | 2 | 2018 | 336 | 0.130 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 129 | 0.120 |
Why?
|
| Aftercare | 1 | 2017 | 146 | 0.120 |
Why?
|
| Heart Transplantation | 1 | 2022 | 859 | 0.120 |
Why?
|
| Registries | 1 | 2021 | 1434 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 373 | 0.110 |
Why?
|
| Guanine Nucleotides | 1 | 2013 | 15 | 0.110 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 35 | 0.110 |
Why?
|
| Thionucleotides | 1 | 2013 | 21 | 0.110 |
Why?
|
| Survivors | 2 | 2017 | 339 | 0.110 |
Why?
|
| Biotransformation | 1 | 2013 | 50 | 0.110 |
Why?
|
| Drug Evaluation | 1 | 2013 | 105 | 0.110 |
Why?
|
| Xanthine Oxidase | 1 | 2013 | 42 | 0.110 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 40 | 0.110 |
Why?
|
| Heart-Assist Devices | 1 | 2022 | 1026 | 0.110 |
Why?
|
| Methyltransferases | 1 | 2013 | 72 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 424 | 0.100 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2012 | 29 | 0.100 |
Why?
|
| Glutathione Peroxidase | 1 | 2012 | 52 | 0.100 |
Why?
|
| Pediatrics | 1 | 2021 | 1158 | 0.100 |
Why?
|
| Infant | 6 | 2024 | 12610 | 0.100 |
Why?
|
| Glutathione Transferase | 1 | 2012 | 156 | 0.090 |
Why?
|
| Superoxide Dismutase | 1 | 2012 | 181 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 1245 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 2001 | 818 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 508 | 0.080 |
Why?
|
| Heart Failure | 1 | 2022 | 2297 | 0.080 |
Why?
|
| Adult | 6 | 2024 | 29459 | 0.080 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 907 | 0.080 |
Why?
|
| Antifungal Agents | 2 | 2021 | 291 | 0.070 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 615 | 0.070 |
Why?
|
| Age Factors | 3 | 2024 | 2815 | 0.070 |
Why?
|
| Genotype | 1 | 2012 | 2569 | 0.060 |
Why?
|
| Risk Factors | 4 | 2023 | 10278 | 0.060 |
Why?
|
| Blood Glucose Self-Monitoring | 3 | 2001 | 122 | 0.060 |
Why?
|
| Blood Glucose | 3 | 1999 | 1133 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 3402 | 0.060 |
Why?
|
| Patient Compliance | 2 | 2017 | 470 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 2654 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2023 | 4821 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2022 | 16339 | 0.050 |
Why?
|
| Vomiting | 1 | 2023 | 103 | 0.050 |
Why?
|
| Semen | 1 | 2023 | 77 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 186 | 0.050 |
Why?
|
| Levofloxacin | 1 | 2022 | 46 | 0.050 |
Why?
|
| United States | 3 | 2023 | 10884 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2021 | 73 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2022 | 116 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 215 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2024 | 493 | 0.040 |
Why?
|
| Diarrhea | 1 | 2022 | 315 | 0.040 |
Why?
|
| Oocytes | 1 | 2021 | 299 | 0.040 |
Why?
|
| Insulin | 2 | 2001 | 1203 | 0.040 |
Why?
|
| Voriconazole | 1 | 2018 | 34 | 0.040 |
Why?
|
| Lipopeptides | 1 | 2018 | 33 | 0.040 |
Why?
|
| Amphotericin B | 1 | 2018 | 90 | 0.040 |
Why?
|
| Echinocandins | 1 | 2018 | 44 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 439 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 92 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2022 | 827 | 0.040 |
Why?
|
| Parent-Child Relations | 1 | 1999 | 248 | 0.030 |
Why?
|
| Disease Progression | 1 | 2023 | 2084 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1526 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1425 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2021 | 8275 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 5169 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1158 | 0.030 |
Why?
|
| Disease Management | 1 | 1998 | 528 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1630 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 1720 | 0.030 |
Why?
|
| Parenting | 1 | 1997 | 333 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2022 | 2603 | 0.020 |
Why?
|
| Middle Aged | 1 | 2012 | 26676 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2022 | 12272 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3131 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 3424 | 0.020 |
Why?
|
| Emergency Service, Hospital | 2 | 2001 | 1071 | 0.010 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2001 | 161 | 0.010 |
Why?
|
| Office Visits | 1 | 1999 | 76 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 1999 | 438 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2001 | 2182 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 1997 | 372 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2001 | 6123 | 0.010 |
Why?
|
| Time Factors | 1 | 1999 | 6302 | 0.000 |
Why?
|